New oncology drugs and osteonecrosis of the jaw (ONJ)

J Tenn Dent Assoc. 2009 Fall;89(4):36-8; quiz 38-9.

Authors

Cesar A Migliorati¹, J Stansill Covington 3rd

Affiliation

¹ Department of Biologic and Diagnostic Sciences, University of Tennessee Health Sciences Center, College of Dentistry, USA.

PMID: 20102031

No abstract available

MeSH terms

Angiogenesis Inhibitors / adverse effects
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / adverse effects*
Bone Density Conservation Agents / adverse effects
Denosumab
Diphosphonates / adverse effects
Humans
Jaw Diseases / etiology*
Osteonecrosis / etiology*
RANK Ligand / adverse effects

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Bone Density Conservation Agents
Diphosphonates
RANK Ligand
Denosumab